Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study.

Drugs R D · 2017 · PMC5694422 · PMID 28895069

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp = 0.09so close (0.05 < p ≤ 0.1)

This study demonstrated no differences in terms of drug tolerability or patient-reported symptoms of disease, but showed a trend towards superiority of the 4/2 schedule over the CDD schedule in terms of TTP (9.9 months for 4/2 schedule vs. 7.1 months for CDD, HR 0.77, 95% CI 0.57–1.04, p = 0.09).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.